David Jamieson
Impact in
- Oncology top 5%
- Vascular Tumors and Angiosarcomas
- PARP inhibition in cancer therapy
- Cancer Cells and Metastasis
- Cancer Research top 10%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 16
- HER2/EGFR in Cancer Research 4
- Drug Transport and Resistance Mechanisms 4
- Co-authors
- Alan V. BoddyMark VerrillGareth J. VealScott KellermanMichael ColeJ SluddenNicola J. CurtinMartin J. Griffin
- Journals
- British Journal of Cancer (5 papers)European Journal of Cancer (3 papers)Contraception (3 papers)Clinical Cancer Research (2 papers)AIDS (2 papers)
- Partner nations
- United KingdomUnited StatesSwitzerland
In The Last Decade
David Jamieson
40 papers receiving 1.5k citations
Hit Papers
Peers
Comparison fields: 5 of 126
- Oncology 731
- Cancer Research 217
- Pulmonary and Respiratory Medicine 383
- Pharmacology 101
- Hepatology 78
Countries citing papers authored by David Jamieson
This map shows the geographic impact of David Jamieson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Jamieson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Jamieson more than expected).
Fields of papers citing papers by David Jamieson
This network shows the impact of papers produced by David Jamieson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Jamieson. The network helps show where David Jamieson may publish in the future.
Co-authorship network
The 25 scholars most cited alongside David Jamieson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 0 | |
| 2 | 2020 | 9 | |
| 3 | 2019 | 29 | |
| 4 | 2017 | 0 | |
| 5 | Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial Hit paper breakdown → | 2017 | 340 |
| 6 | 2016 | 13 | |
| 7 | 2016 | 6 | |
| 8 | 2016 | 58 | |
| 9 | 2016 | 126 | |
| 10 | 2016 | 33 | |
| 11 | 2016 | 50 | |
| 12 | 2016 | 99 | |
| 13 | 2014 | 30 | |
| 14 | 2013 | 5 | |
| 15 | 2013 | 3 | |
| 16 | 2012 | 31 | |
| 17 | 2011 | 86 | |
| 18 | 2011 | 30 | |
| 19 | 2006 | 20 | |
| 20 | 1999 | 13 |
About David Jamieson
David Jamieson is a scholar working on Oncology, Toxicology, Pediatrics, Perinatology and Child Health, Infectious Diseases and Immunology, having authored 42 papers that have together received 1.5k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (6 papers), HIV/AIDS Research and Interventions (6 papers), Acute Lymphoblastic Leukemia research (6 papers), DNA Repair Mechanisms (4 papers), Childhood Cancer Survivors' Quality of Life (4 papers), HER2/EGFR in Cancer Research (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Drug Transport and Resistance Mechanisms (4 papers). The work is most often cited by research in Oncology (731 citations), Cancer Research (217 citations), Pulmonary and Respiratory Medicine (383 citations), Pharmacology (101 citations) and Hepatology (78 citations). David Jamieson has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include Alan V. Boddy, Mark Verrill, Gareth J. Veal, Scott Kellerman, Michael Cole, J Sludden, Nicola J. Curtin, Martin J. Griffin, Laura Ogle and Ruth Plummer. Their work appears in journals such as British Journal of Cancer, European Journal of Cancer, Contraception, Clinical Cancer Research and AIDS.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.